Atlas Prep HQ · Research Library · Updated August 2026

Peptide Master Guide [2026]

A practical, research-focused guide to understanding today’s most talked-about peptides — what they are, what researchers are studying, how they differ, and what the evidence actually shows.

Evidence-based · Research-focused ~35 min read

Quick Summary

The 60-Second Version

Everything else on this page expands on these nine points.

01
Peptides are short amino-acid chains that can act as biological signaling molecules — many of the body's own signals already are peptides.
02
Different peptides act through very different biological pathways. 'Peptides' is a category, not a mechanism.
03
Some compounds have meaningful human clinical evidence; many others remain largely preclinical. The difference matters.
04
Route, half-life, and formulation can significantly change how a compound behaves and how it was studied.
05
Reported protocols online are not automatically clinically validated protocols — most are community references.
06
Evidence should be evaluated peptide by peptide, never by treating 'peptides' as one thing.
07
Storage and reconstitution requirements vary by compound and directly affect stability and potency.
08
Regulatory and WADA status vary between compounds — approval for one says nothing about another.
09
Source quality and study quality both matter when evaluating any peptide claim.

Foundations

What Are Peptides?

The short version. For the full foundations course, read Peptide Foundations.

A peptide is a short chain of amino acids. Link a few amino acids together and you get a peptide; link hundreds and you get a protein. That’s the whole structural definition.

They matter because biology runs on them. Many of the body’s own signals — hormones, neurotransmitters, immune messengers — are peptides. When researchers study a synthetic peptide, they are usually probing a signaling pathway the body already uses.

Researchers modify natural peptides to change their behavior. Analogues are engineered to alter half-life, stability, receptor selectivity, bioavailability, or delivery — which is why a modified version of a natural signal can behave very differently from the original.

Read Peptide Foundations

What peptides may do in research

Influence receptor signaling
Affect metabolic pathways
Modulate hormone release
Influence tissue-repair pathways
Affect inflammatory signaling
Influence appetite signaling
Affect neurological pathways
Influence collagen production

What peptides do not automatically mean

Clinically proven
FDA approved
Safe for everyone
Effective in humans because an animal study was positive
Equivalent to another peptide
Appropriate without medical oversight

The Library

Browse Peptides by Goal

Start with the biological system or research area you're interested in. Every card below is generated from the Atlas library.

The full library lives on its own page — filterable, searchable, and built for side-by-side comparison.

52 entries across 11 research categories. If you want deep profiles, common dosing ranges, and evidence tiers, that is the place.

Open the Peptide Directory

ENDURE BIOLABS · VENDOR CARD

VERIFIED

· WHY ENDURE BIOLABS

RESEARCH-GRADE
OR DON'T BOTHER.

Atlas Prep HQ links to vendors that publish third-party testing, ship cold-chain from the United States, and make Certificates of Analysis available on request — the same standard we apply to every research claim on this site.

01 · PURITY

99%+

HPLC-VERIFIED

02 · TESTING

THIRD-PARTY

INDEPENDENT LAB

03 · COA

PER BATCH

AVAILABLE ON REQUEST

04 · SHIPPING

USA

COLD-CHAIN PACKED

CODEATLAS· 25% OFF

SHOP ENDURE BIOLABS · 25% OFF

Deep Dives

Peptide Spotlights

Twelve compounds that anchor most modern peptide discussions — condensed from their full Atlas library profiles.

Spotlight 01

BPC-157

Body Protection Compound-157, a synthetic 15-amino-acid gastric peptide analogue

HealingPreclinical Evidence

What it is

BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. It is the single most discussed 'healing' peptide in the community — studied primarily for tissue repair, cytoprotection, and gastrointestinal healing pathways.

Why it’s interesting

Few compounds have such a wide animal literature: rodent studies report effects on tendon, ligament, muscle, bone, nerve, and gut injury. That consistency is exactly why researchers keep returning to it — and why the absence of controlled human trials is so striking.

How it works

Proposed mechanisms include nitric-oxide signaling modulation, VEGF and growth-factor pathway activity, angiogenesis, and fibroblast-driven repair — mostly mapped in cell and animal models.

What the research says

Human evidence

Meaningful controlled human efficacy evidence is absent.

Preclinical evidence

A large preclinical literature in rodents reports effects on tendon, ligament, muscle, bone, nerve, gastrointestinal injury, angiogenesis, and nitric-oxide signaling.

Quick reference

Route: Injectable
Frequency: Once daily in the community protocol.
Timing: No evidence-based time-of-day requirement.
Evidence level: Preclinical evidence

Reported research context

Commonly referenced range: 200–600 mcg/day with gradual titration. community sources' 2026 dosage guide describes roughly 250–500 mcg/day as the mo…
Cycle context: 4–8 weeks
Reconstitution: 1 mL bacteriostatic water per 10 mg vial = 10 mg/mL.

Published / reported research context — not a treatment protocol.

Important considerations

The gap between popularity and proof is the story here. Human pharmacokinetics, dose-response, and long-term safety are unknown, and angiogenesis-related mechanisms raise theoretical questions that only human trials can answer.

Read the Full BPC-157 Guide

Spotlight 02

TB-500

Synthetic thymosin-beta-4-derived research peptide, commonly associated with the Ac-LKKTET…

HealingPreclinical Evidence

What it is

TB-500 is a synthetic fragment-based analogue associated with thymosin beta-4, a naturally occurring peptide involved in cell migration and tissue repair. It is usually discussed alongside BPC-157 in recovery contexts.

Why it’s interesting

Thymosin beta-4 biology touches actin regulation, cell migration, blood-vessel formation, and inflammation — the core machinery of wound repair. That made its analogues a natural target for soft-tissue research.

How it works

Thymosin beta-4-related signaling influences actin dynamics and cell migration, supporting the repair and remodeling processes studied in preclinical injury models.

What the research says

Human evidence

There is no established controlled human evidence for 'TB-500' as a standardized injury-recovery drug.

Preclinical evidence

Thymosin-beta-4 and related sequence research shows actin binding, cell migration, angiogenesis, and wound-repair effects in animals.

Quick reference

Route: Injectable
Frequency: Once daily in the community current page.
Timing: No established timing requirement.
Evidence level: Preclinical evidence

Reported research context

Commonly referenced range: community sources experimental reference: 500–1,000 mcg/day. There is no validated human dose for 'TB-500' as a standard…
Cycle context: 8–12 weeks
Reconstitution: 1 mL bacteriostatic water per 10 mg vial = 10 mg/mL.

Published / reported research context — not a treatment protocol.

Important considerations

Human efficacy evidence for TB-500 itself is essentially absent, and thymosin beta-4-related compounds are prohibited in sport. Treat community protocols as community practice, not validated medicine.

Read the Full TB-500 Guide

Spotlight 03

Semaglutide

Long-acting GLP-1 receptor agonist peptide

Fat LossStrong Human Evidence

What it is

Semaglutide is a long-acting GLP-1 receptor agonist and one of the most clinically validated molecules ever associated with the word 'peptide.' It is FDA-approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy).

Why it’s interesting

It is the proof that peptide signaling drugs can be blockbuster medicine: large randomized trials show substantial, reproducible weight loss and cardiovascular outcome benefits in defined populations.

How it works

Activates GLP-1 receptors in the pancreas, gut, and brain — enhancing glucose-dependent insulin secretion, slowing gastric emptying, and reducing appetite through central satiety pathways.

What the research says

Human evidence

Semaglutide has extensive randomized human evidence and regulatory approval for type 2 diabetes, chronic weight management, and selected cardiovascular-risk indications.

Preclinical evidence

Animal GLP-1 studies established appetite, insulin, glucagon, and gastric mechanisms that were subsequently validated in large human programs.

Quick reference

Route: Injectable
Frequency: Once weekly.
Timing: Same day each week, with or without meals; follow the specific approve…
Evidence level: Strong human evidence

Reported research context

Commonly referenced range: For chronic weight management, the labeled SC schedule commonly titrates 0.25 mg weekly upward every 4 weeks to 2.4 mg w…
Cycle context: Ongoing / long-term
Reconstitution: Approved pens are not reconstituted by patients. the community 10 mg lyophilized research-…

Published / reported research context — not a treatment protocol.

Important considerations

GI side effects are common, lean-mass loss accompanies weight reduction, and much of the gray-market 'research peptide' supply chain around semaglutide has no quality oversight. Approved products follow the label — nothing else is validated.

Read the Full Semaglutide Guide

Spotlight 04

Tirzepatide

39-amino-acid dual GIP/GLP-1 receptor agonist peptide

Fat LossStrong Human Evidence

What it is

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). It represents the 'multi-agonist' generation of metabolic peptides.

Why it’s interesting

In head-to-head and placebo-controlled trials it produced some of the largest weight reductions ever recorded for a pharmacotherapy, which is why dual and triple agonists now dominate metabolic research.

How it works

Combines GIP and GLP-1 receptor activation, pairing enhanced insulin secretion and appetite suppression with GIP-pathway effects on adipose and energy handling.

What the research says

Human evidence

Tirzepatide has extensive randomized human evidence and regulatory approval for type 2 diabetes and chronic weight management, with additional cardiometabolic outcome research.

Preclinical evidence

Preclinical dual GIP/GLP-1 agonist work predicted strong glucose and body-weight effects that were then confirmed in large human trials.

Quick reference

Route: Injectable
Frequency: Once weekly.
Timing: Same day each week; may be taken with or without food.
Evidence level: Strong human evidence

Reported research context

Commonly referenced range: Labeled once-weekly therapy starts at 2.5 mg and can titrate in 2.5 mg increments after at least 4 weeks, up to 15 mg we…
Cycle context: Ongoing / long-term
Reconstitution: Approved Mounjaro/Zepbound products are supplied in ready-to-use delivery systems and are…

Published / reported research context — not a treatment protocol.

Important considerations

Strong human evidence applies to the approved, titrated products — not to compounded or research-vial versions. GI tolerability, gallbladder risk, and lean-mass preservation all matter in real use.

Read the Full Tirzepatide Guide

Spotlight 05

Cagrilintide

Long-acting acylated amylin analogue

Fat LossStrong Human Evidence

What it is

Cagrilintide is a long-acting amylin analogue in late-stage clinical development for obesity. Amylin is a naturally occurring peptide hormone co-secreted with insulin that signals satiety.

Why it’s interesting

It targets a different appetite pathway than GLP-1 drugs, and its combination with semaglutide (CagriSema) is one of the few peptide 'stacks' actually being tested in large randomized human trials.

How it works

Activates amylin receptors in the CNS and gastrointestinal system, increasing satiety, slowing gastric emptying, and reducing food intake; acylation extends exposure to allow once-weekly dosing.

What the research says

Human evidence

Cagrilintide has substantial randomized human trial evidence showing dose-dependent weight loss and appetite effects in people with overweight or obesity.

Preclinical evidence

Animal models supported prolonged amylin-receptor agonism, reduced food intake, and body-weight reduction and informed human dose development.

Quick reference

Route: Injectable
Frequency: Once weekly.
Timing: Same day each week; time of day is not usually critical.
Evidence level: Strong human evidence

Reported research context

Commonly referenced range: Human trials have studied once-weekly dose escalation up to 4.5 mg. Community reference: 0.6 → 1.2 → 2.4 → 4.5 mg weekly…
Cycle context: 12–16+ weeks
Reconstitution: 1 mL bacteriostatic water per 5 mg vial = 5 mg/mL.

Published / reported research context — not a treatment protocol.

Important considerations

Human trial evidence is strong for weight endpoints, but cagrilintide is investigational — final regulatory labeling, long-term comparative safety, and real-world use outside studied populations remain open questions.

Read the Full Cagrilintide Guide

Spotlight 06

Ipamorelin

Selective growth-hormone secretagogue pentapeptide and GHSR-1a agonist

Growth HormoneLimited Human Evidence

What it is

Ipamorelin is a selective growth-hormone secretagogue — a pentapeptide that stimulates the pituitary to release growth hormone through the ghrelin/GHS receptor without the broad hormonal spillover of older secretagogues.

Why it’s interesting

Its selectivity is the appeal: in studies it raised GH without meaningfully raising cortisol or prolactin, making it the cleaner member of the GHRP family and a fixture in GH-signaling research discussions.

How it works

Binds the growth-hormone secretagogue receptor (GHS-R1a) on pituitary somatotrophs, triggering pulsatile GH release that mimics a physiological pulse rather than sustained elevation.

What the research says

Human evidence

Early human pharmacology studies show that ipamorelin can stimulate GH release with relative selectivity compared with older secretagogues.

Preclinical evidence

Animal and receptor studies demonstrate selective GHSR agonism and GH release with less ACTH/cortisol stimulation than some older GHRPs.

Quick reference

Route: Injectable
Frequency: Once daily in the community protocol.
Timing: Often bedtime and/or fasted in research practice to align with GH puls…
Evidence level: Limited human evidence

Reported research context

Commonly referenced range: 100–300 mcg/day; 200 mcg/day is listed as a common midpoint.
Cycle context: 8–12 weeks
Reconstitution: 1 mL bacteriostatic water per 10 mg vial = 10 mg/mL.

Published / reported research context — not a treatment protocol.

Important considerations

Human studies exist but are small and short. Long-term safety, body-composition outcomes, and supraphysiologic GH exposure are not established — and GH secretagogues are WADA-prohibited in sport.

Read the Full Ipamorelin Guide

Spotlight 07

Tesamorelin

Synthetic stabilized growth hormone-releasing hormone analogue

Growth HormoneStrong Human Evidence

What it is

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH) and one of the few entries in this library with full FDA approval — indicated for excess visceral fat in people with HIV-associated lipodystrophy (Egrifta).

Why it’s interesting

It demonstrates what a validated GHRH-pathway peptide looks like: randomized trials show measurable visceral adipose tissue reduction in the approved population, with defined dosing and monitoring.

How it works

Binds pituitary GHRH receptors, stimulating endogenous pulsatile GH secretion, which secondarily raises IGF-1 — the axis through which its metabolic effects are mediated.

What the research says

Human evidence

Tesamorelin has strong randomized human evidence and FDA approval for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.

Preclinical evidence

Preclinical GHRH biology was well established before human development.

Quick reference

Route: Injectable
Frequency: Once daily.
Timing: Label does not require a performance-specific clock time; community so…
Evidence level: Strong human evidence

Reported research context

Commonly referenced range: Current U.S. formulations differ: FDA labeling lists Egrifta WR 1.28 mg SC once daily and Egrifta SV 1.4 mg SC once dail…
Cycle context: Ongoing / long-term
Reconstitution: Product-specific and not interchangeable. Egrifta WR and Egrifta SV use different vial str…

Published / reported research context — not a treatment protocol.

Important considerations

Approval is indication-specific. Glucose tolerance, IGF-1 elevation, and injection-site reactions require monitoring, and extrapolating the HIV-lipodystrophy data to general 'fat loss' or anti-aging use is not evidence-based.

Read the Full Tesamorelin Guide

Spotlight 08

Semax

Met-Glu-His-Phe-Pro-Gly-Pro, an ACTH(4–7)-derived heptapeptide analogue

CognitiveLimited Human Evidence

What it is

Semax is a synthetic heptapeptide derived from a fragment of ACTH, developed in Russia, where it has regulatory approval as a nasal-spray nootropic. It is one of the few cognitive peptides with any formal clinical-use history.

Why it’s interesting

Intranasal delivery, a real (if geographically narrow) regulatory history, and research into stroke recovery, attention, and stress adaptation make Semax the most clinically anchored of the cognitive peptides.

How it works

Proposed mechanisms include modulation of BDNF and neurotrophin expression, dopaminergic and serotonergic signaling, and neuroprotective pathways — studied mostly in Russian-language clinical literature and animal models.

What the research says

Human evidence

Semax has human clinical use and research history in Russia, including neurologic indications, but much of the literature is regional and not matched by large internationally replicated modern trials.

Preclinical evidence

Animal and cellular studies report neuroprotection, BDNF/TrkB effects, monoamine changes, antioxidant activity, and improved outcomes after ischemic injury.

Quick reference

Route: Intranasal
Frequency: Once daily in the community SC protocol; intranasal clinical protocols…
Timing: Usually daytime because the target is cognition/neurologic function; n…
Evidence level: Limited human evidence

Reported research context

Commonly referenced range: community sources SC reference: 300–800 mcg/day. Most human clinical literature uses intranasal Semax with protocol-spec…
Cycle context: 4–8 weeks
Reconstitution: 1 mL bacteriostatic water per 10 mg vial = 10 mg/mL for SC research use.

Published / reported research context — not a treatment protocol.

Important considerations

The evidence base is regionally concentrated, methodologically uneven, and rarely replicated by independent international groups. Intranasal research-vial use is not equivalent to the regulated product.

Read the Full Semax Guide

Spotlight 09

Selank

Thr-Lys-Pro-Arg-Pro-Gly-Pro, a synthetic tuftsin analogue

CognitiveLimited Human Evidence

What it is

Selank is a synthetic heptapeptide derived from the immune peptide tuftsin, developed alongside Semax in Russia, where it is approved as an anxiolytic. It sits at the intersection of immune signaling and anxiety research.

Why it’s interesting

A tuftsin-derived compound with an actual national approval for anxiety is unusual in this space. Studies report anxiolytic effects without classic benzodiazepine-type sedation, which keeps research interest alive.

How it works

Proposed effects include modulation of GABAergic signaling, monoamine metabolism, and immune-derived signaling inherited from its tuftsin backbone — though the precise receptor pharmacology remains uncertain.

What the research says

Human evidence

Small human studies and Russian clinical experience suggest anxiolytic effects, but the literature is relatively limited, regionally concentrated, and lacks large independent confirmatory trials.

Preclinical evidence

Animal and cell studies report anxiolytic effects, changes in GABA-related signaling, neurotrophins, and stress-response genes.

Quick reference

Route: Intranasal
Frequency: Once daily in the community SC protocol; intranasal studies may use di…
Timing: Often daytime or divided; adjust to sleep/mood effects. No internation…
Evidence level: Limited human evidence

Reported research context

Commonly referenced range: community sources SC reference: 300–500 mcg/day. Much of the human literature and Russian use is intranasal and uses for…
Cycle context: 4 weeks
Reconstitution: 0.5 mL bacteriostatic water per 5 mg vial = 10 mg/mL for SC research use.

Published / reported research context — not a treatment protocol.

Important considerations

As with Semax, the human literature is small, region-specific, and lightly replicated. Long-term data are thin, and community intranasal/subcutaneous protocols are not validated equivalents of the approved product.

Read the Full Selank Guide

Spotlight 10

GHK-Cu

Glycyl-L-histidyl-L-lysine copper(II) complex; copper tripeptide-1

HealingLimited Human Evidence

What it is

GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma and saliva. Its research centers on collagen synthesis, skin quality, wound repair, and tissue remodeling — and it has decades of cosmetic use behind it.

Why it’s interesting

It is the rare compound where topical human evidence genuinely exists: dermatologic studies and long cosmetic use support effects on skin appearance, making it the most human-anchored 'repair' peptide in the library.

How it works

Binds and delivers copper to enzymes involved in collagen cross-linking and antioxidant defense, while influencing growth factors, matrix metalloproteinases, and broad tissue-remodeling gene programs.

What the research says

Human evidence

Human evidence is strongest for topical/cosmetic uses, where small clinical studies and decades of dermatologic use support effects on skin appearance and wound-related biology.

Preclinical evidence

Cell and animal studies support wound healing, collagen remodeling, angiogenesis, antioxidant activity, and broad gene-expression effects.

Quick reference

Route: Topical
Frequency: Once daily, 5 days on / 2 days off in the community protocol.
Timing: Any consistent time; no validated timing advantage.
Evidence level: Limited human evidence

Reported research context

Commonly referenced range: 1–2 mg/day SC with titration; topical GHK-Cu has a different evidence base and cannot be dose-converted from injectable…
Cycle context: 8–12 weeks
Reconstitution: 2.5 mL bacteriostatic water per 50 mg vial = 20 mg/mL.

Published / reported research context — not a treatment protocol.

Important considerations

Topical and injectable evidence must never be merged. Injectable GHK-Cu pharmacokinetics, systemic copper handling, and long-term safety are essentially unstudied — the cosmetic data do not transfer.

Read the Full GHK-Cu Guide

Spotlight 11

Epitalon

Ala-Glu-Asp-Gly (AEDG), also called Epithalon

LongevityLimited Human Evidence

What it is

Epitalon (Epithalon) is a synthetic tetrapeptide derived from a pineal-gland extract, studied mainly by the Khavinson research program for telomerase activity, circadian regulation, and aging biology.

Why it’s interesting

It is one of the only compounds in the longevity category with any human data at all — small studies report effects on circadian markers and age-related outcomes, which is more than most 'anti-aging peptides' can claim.

How it works

In-vitro studies report telomerase activation and telomere effects; animal and small human studies suggest pineal/circadian signaling and melatonin-related effects. The systemic longevity pathway remains unproven.

What the research says

Human evidence

Small and older human studies from the Khavinson research program have reported effects on circadian markers, mortality, or age-related outcomes, but the studies are limited by size, geography, methodology, and independe…

Preclinical evidence

Cell studies report telomerase activation and telomere-related effects; animal work reports circadian, antioxidant, reproductive, and lifespan-related signals.

Quick reference

Route: Injectable
Frequency: Once daily during the short cycle.
Timing: Often evening/bedtime in the community protocol because of the circadi…
Evidence level: Limited human evidence

Reported research context

Commonly referenced range: 5 mg/day for 20 consecutive days; an alternative listed is 10 mg/day for 10 days. These are not established clinical sta…
Cycle context: 10–20 days
Reconstitution: 1 mL bacteriostatic water per 10 mg vial = 10 mg/mL.

Published / reported research context — not a treatment protocol.

Important considerations

The human studies are small, old, geographically concentrated, and lightly replicated by independent groups. 'Telomerase activation in a dish' is not a demonstrated lifespan effect in humans.

Read the Full Epitalon Guide

Spotlight 12

MOTS-c

Mitochondrial ORF of the 12S rRNA-c, a mitochondrial-derived 16-amino-acid peptide

LongevityPreclinical Evidence

What it is

MOTS-c is a mitochondrial-derived peptide — a 16-amino-acid signal encoded in mitochondrial DNA — studied for its role in metabolic regulation, exercise capacity, and cellular stress adaptation.

Why it’s interesting

Mitochondrial-derived peptides are a genuinely new biology: MOTS-c appears to act as an exercise-mimetic signal in animal models, linking mitochondrial stress to whole-body metabolic adaptation.

How it works

Research points to AMPK-pathway activation and folate-methionine cycle effects that shift glucose utilization and metabolic flexibility, particularly under metabolic stress in animal models.

What the research says

Human evidence

As of 2026, meaningful human interventional evidence for administered MOTS-c remains very limited.

Preclinical evidence

Mouse studies report improved insulin sensitivity, exercise capacity, metabolic flexibility, and stress adaptation, partly through AMPK and nuclear signaling.

Quick reference

Route: Injectable
Frequency: Once daily in the community protocol.
Timing: No established time-of-day requirement; exercise-related timing remain…
Evidence level: Preclinical evidence

Reported research context

Commonly referenced range: 200–1,000 mcg/day with gradual titration. No validated human therapeutic dose exists.
Cycle context: 8–12 weeks
Reconstitution: 1 mL bacteriostatic water per 10 mg vial = 10 mg/mL.

Published / reported research context — not a treatment protocol.

Important considerations

Human trials are early and small. The 'exercise in a vial' framing popular online runs far ahead of the evidence — animal exercise-capacity findings have not been confirmed as meaningful human outcomes.

Read the Full MOTS-c Guide

Method

How to Approach Peptide Research

A seven-step framework for evaluating any compound — before protocols, before sources, before anything else.

1
Define the goal
What biological outcome or research question is actually being considered? 'Recovery,' 'fat loss,' and 'focus' point to entirely different pathways and entirely different compounds.
2
Identify the compound
Don't choose a peptide because it's popular. Understand the pathway it touches and whether that pathway matches the goal — mechanism first, marketing last.
3
Check the evidence level
Was it studied in cells, animals, small human trials, or large randomized trials? Each step up that ladder is worth more than every step below it combined.
4
Understand the research protocol
Look at dose, frequency, duration, route, and the population studied. A result in one route or population does not transfer automatically to another.
5
Review safety information
Known side effects, contraindications, biomarker changes, drug interactions, and — just as important — the long-term unknowns. 'No data' is not 'no risk.'
6
Verify product and source quality
Identity testing, purity, batch-specific Certificates of Analysis, and independent third-party testing matter. Atlas Prep does not endorse vendors — verify, don't trust.
7
Monitor appropriately
Relevant biomarkers and medical supervision depend on the compound and the person. Compounds that move hormones, glucose, or blood pressure demand real monitoring.

Stacks

Common Stacks

Why certain compounds are discussed together — and what kind of evidence actually sits behind each pairing. A stack is only 'proven' when the combination itself was tested.

Recovery

BPC-157 + TB-500

Why they’re discussed together

Pairs BPC-157's preclinical cytoprotective and angiogenic rationale with thymosin-beta-4-related cell-migration and repair biology — two different slices of the tissue-repair machinery.

Evidence

Preclinical + community use. No controlled human trial has evaluated the combination.

BPC-157 TB-500

Growth-hormone signaling

CJC-1295 (no DAC) + Ipamorelin

Why they’re discussed together

A GHRH-pathway analogue paired with a selective ghrelin-receptor secretagogue — the two arms of pituitary GH release. The rationale is complementary signaling, not proven synergy.

Evidence

Mechanistic rationale + community use. The pair has not been validated in controlled human trials.

CJC-1295 NO DAC + Ipamorelin Ipamorelin

Metabolic

Cagrilintide + Semaglutide

Why they’re discussed together

Amylin-pathway satiety signaling plus GLP-1 appetite and gastric-emptying effects — two distinct appetite systems targeted at once. Developed clinically as CagriSema.

Evidence

Strong human evidence — one of the only peptide combinations tested in large randomized trials.

Cagrilintide Semaglutide

Skin & tissue remodeling

BPC-157 + GHK-Cu

Why they’re discussed together

Discussed together because they act on different repair pathways — cytoprotective signaling versus copper-dependent collagen remodeling and matrix turnover.

Evidence

Mechanistic rationale + community use. No controlled human evidence for the combination.

BPC-157 GHK-Cu

Reference

Peptide Timing Reference

When timing is biology, when it's the trial schedule — and when it's just community habit.

Peptide	Reported timing	Frequency	Route	Why timing may matter	Evidence context
Semaglutide	Same day each week, with or without meals; follow the specific approve…	Once weekly.	Injectable	Long half-life (~1 week) makes time of day irrelevant; consistency of the weekly day aids adherence.	Clinical trial schedule
Cagrilintide	Same day each week; time of day is not usually critical.	Once weekly.	Injectable	Long-acting acylated analogue; same-day-weekly dosing matches trial protocols.	Clinical trial schedule
Tirzepatide	Same day each week; may be taken with or without food.	Once weekly.	Injectable	Weekly formulation; timing is about routine, not biology.	Clinical trial schedule
Ipamorelin	Often bedtime and/or fasted in research practice to align with GH puls…	Once daily in the community protocol.	Injectable	Pulsatile GH secretagogue; evening dosing is intended to align with natural nocturnal GH pulses.	Community practice — limited clinical validation
Tesamorelin	Label does not require a performance-specific clock time; community so…	Once daily.	Injectable	Approved labeling uses once-daily bedtime dosing to complement physiologic GH rhythm.	Approved label
Epitalon	Often evening/bedtime in the community protocol because of the circadi…	Once daily during the short cycle.	Injectable	Circadian research hypothesis motivates evening timing in community protocols.	Community practice — limited clinical validation
DSIP	Typically evening before bedtime in research/community use.	Once daily.	Injectable	Studied around sleep; evening use follows the research question itself.	Research context, historical human studies
Semax	Usually daytime because the target is cognition/neurologic function; n…	Once daily in the community SC protocol; intranasal cli…	Intranasal	Daytime use is typical in the cognitive literature; stimulating effects make pre-bed use illogical.	Clinical-use history (regional)
PT-141	At least 45 minutes before anticipated sexual activity for the approve…	As needed under the approved regimen, not daily.	Injectable	Onset over hours drives the 'several hours before' guidance on the approved label.	Approved label (Vyleesi)
BPC-157	No evidence-based time-of-day requirement.	Once daily in the community protocol.	Injectable	No evidence-based time-of-day requirement; consistent daily timing is a community convention.	Community practice — limited clinical validation
GHK-Cu	Any consistent time; no validated timing advantage.	Once daily, 5 days on / 2 days off in the community pro…	Topical	Topical cosmetic use follows skincare routine timing; no validated systemic timing standard.	Cosmetic-use convention
MOTS-c	No established time-of-day requirement; exercise-related timing remain…	Once daily in the community protocol.	Injectable	Pre-exercise timing is a community extrapolation of animal exercise-mimetic findings.	Community practice — limited clinical validation

Practical

Reconstitution & Storage

The overview. For the full manual, use the dedicated Atlas resources below.

Lyophilized peptides

Lyophilization is freeze-drying: water is removed under vacuum so the peptide survives shipping and storage. Most research peptides arrive as a lyophilized puck or powder because the dry form is dramatically more stable than a solution.

Reconstitution

Reconstitution means mixing the powder with a diluent — typically bacteriostatic water — before use. The volume of diluent sets the concentration, and the concentration determines how much liquid a given dose occupies.

Storage

Temperature, light, moisture, contamination, and time-after-reconstitution all degrade peptides. The common pattern across the library: lyophilized frozen, reconstituted at 2–8 °C, protected from light, no freeze-thaw cycles.

Compound-Specific Storage in the Library Reconstitution Calculator

Safety

Safety, Side Effects & Regulatory Status

Pulled from the Atlas library. 'Limited human safety data' means exactly that — absence of evidence is not evidence of safety.

Peptide	Commonly reported side effects	Important concerns	Human data	Regulatory / WADA context
Semaglutide	Most common effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal discomfort, reduced appetite and reflux.	GI effects, gallbladder disease, pancreatitis signal; lean-mass loss with rapid weight reduction.	Strong human evidence	FDA-approved (Ozempic/Wegovy/Rybelsus). Not WADA-prohibited at time of writing.
Tirzepatide	Most common effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal discomfort, reduced appetite and reflux.	GI effects, gallbladder risk; boxed warning class considerations for thyroid C-cell findings in rodents.	Strong human evidence	FDA-approved (Mounjaro/Zepbound). Not WADA-prohibited at time of writing.
Cagrilintide	Most common effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal discomfort, reduced appetite and reflux.	GI effects; long-term comparative safety still being established in phase 3 programs.	Strong human evidence	Investigational — not FDA-approved at time of writing.
BPC-157	Controlled human safety data are limited.	No controlled human safety data; angiogenesis-related mechanisms raise theoretical long-term questions.	Preclinical evidence	Not FDA-approved. WADA-prohibited under S0 (unapproved substances).
TB-500	Controlled human safety data are limited.	Human safety data essentially absent; cell-migration biology not characterized in humans.	Preclinical evidence	Not FDA-approved. Thymosin beta-4 and analogues are WADA-prohibited.
Ipamorelin	Potential GH/IGF-axis effects include edema, joint pain, tingling/carpal-tunnel-like symptoms, headache, flushing, increased appetite in som…	Small, short human studies only; long-term effects of repeated GH pulses unknown.	Limited human evidence	Not FDA-approved. GH secretagogues are WADA-prohibited (S2).
Tesamorelin	Labeled effects include injection-site reactions, arthralgia/myalgia, peripheral edema and hypersensitivity.	IGF-1 elevation, glucose intolerance, injection-site reactions — label requires monitoring.	Strong human evidence	FDA-approved (Egrifta) for HIV lipodystrophy. GHRH class is WADA-prohibited (S2).
PT-141	Common labeled effects include nausea, flushing, injection-site reactions and headache.	Nausea, flushing, transient blood-pressure increases; contraindicated with uncontrolled hypertension.	Strong human evidence	FDA-approved (Vyleesi) for HSDD. Not WADA-prohibited at time of writing.
Melanotan II	Reported effects include nausea, flushing, appetite suppression, spontaneous erections/increased libido, fatigue, headache and darkening of…	Nausea, flushing, blood-pressure effects; mole darkening and melanoma-surveillance concerns documented.	Limited human evidence	Not approved anywhere; health regulators in multiple countries have issued warnings.
GHK-Cu	Topical GHK-Cu is generally associated with local irritation or dermatitis in susceptible users.	Topical use well tolerated; injectable systemic safety and copper handling unstudied.	Limited human evidence	Cosmetic topical use widely marketed; injectable use unapproved.
Epitalon	Human safety data are insufficient.	Insufficient human safety data; long-term effects on gene regulation unknown.	Limited human evidence	Not FDA-approved; limited regional clinical history.
Selank	Systematic human safety data are limited.	Small regional evidence base; long-term and independent safety data limited.	Limited human evidence	Approved as an anxiolytic in Russia; not FDA-approved.

Athlete Note — Anti-Doping

WADA status is compound-specific and can change. Growth-hormone secretagogues and releasing factors (S2), unapproved substances (S0), and thymosin-beta-4 analogues appear on the prohibited list, while approved metabolic drugs like semaglutide are not currently prohibited. Never extrapolate from one compound to another — check the current list for the exact substance before any tested competition.

Current WADA Prohibited List

Literacy

How to Read the Evidence

Don't confuse mechanism with proof.

A compound interacting with a biological pathway does not prove a meaningful clinical outcome. Mechanism tells you what a molecule can touch. Evidence tells you what it actually did, in real organisms, under controlled conditions.

Every rung on the ladder below filters out compounds that looked promising on the rung before. Most candidates never climb it — which is exactly why the ladder exists.

The Atlas Rule

“What was actually studied, in whom, for how long, and compared with what?”

1
Cell study
Pathway activity in a dish. Hypothesis-generating only.
2
Animal study
Effects in a living system — but not a human one.
3
Small human study
First signal in people; easily distorted by size and bias.
4
Randomized human trial
Controlled comparison — the first real test of efficacy.
5
Replicated clinical evidence
Independent confirmation across trials and populations.

FAQ

Frequently Asked Questions

ENDURE BIOLABS · VENDOR CARD

VERIFIED

· WHY ENDURE BIOLABS

RESEARCH-GRADE
OR DON'T BOTHER.

01 · PURITY

99%+

HPLC-VERIFIED

02 · TESTING

THIRD-PARTY

INDEPENDENT LAB

03 · COA

PER BATCH

AVAILABLE ON REQUEST

04 · SHIPPING

USA

COLD-CHAIN PACKED

CODEATLAS· 25% OFF

SHOP ENDURE BIOLABS · 25% OFF

Sources

References & Primary Sources

A selection of the primary literature indexed across the Atlas library. Individual peptide pages carry their complete reference lists.

PubMed ClinicalTrials.gov FDA WADA Prohibited List NIH

Educational content only. Nothing on this page is medical advice, a treatment recommendation, or an endorsement of any vendor or product.

The 60-Second Version

What Are Peptides?

What peptides may do in research

What peptides do not automatically mean

Browse Peptides by Goal

RESEARCH-GRADEOR DON'T BOTHER.

Peptide Spotlights

BPC-157

What it is

Why it’s interesting

How it works

What the research says

TB-500

What it is

Why it’s interesting

How it works

What the research says

Semaglutide

What it is

Why it’s interesting

How it works

What the research says

Tirzepatide

What it is

Why it’s interesting

How it works

What the research says

Cagrilintide

What it is

Why it’s interesting

How it works

What the research says

Ipamorelin

What it is

Why it’s interesting

How it works

What the research says

Tesamorelin

What it is

Why it’s interesting

How it works

What the research says

Semax

What it is

Why it’s interesting

How it works

What the research says

Selank

What it is

Why it’s interesting

How it works

What the research says

GHK-Cu

What it is

Why it’s interesting

How it works

What the research says

Epitalon

What it is

Why it’s interesting

How it works

What the research says

MOTS-c

What it is

Why it’s interesting

How it works

What the research says

How to Approach Peptide Research

Define the goal

Identify the compound

Check the evidence level

Understand the research protocol

Review safety information

Verify product and source quality

Monitor appropriately

Common Stacks

BPC-157 + TB-500

CJC-1295 (no DAC) + Ipamorelin

Cagrilintide + Semaglutide

BPC-157 + GHK-Cu

RESEARCH-GRADE
OR DON'T BOTHER.

RESEARCH-GRADE
OR DON'T BOTHER.